G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022

Rhea-AI Summary

G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call on February 23, 2022, at 8:30 a.m. ET to discuss its corporate and financial update for Q4 and full year 2021. The call can be accessed domestically at (866) 763-6020 or internationally at (409) 216-0626 using conference code 5256086. G1 is focused on advancing therapies for cancer, notably through COSELA™ (trilaciclib), and has a diverse clinical pipeline targeting various solid tumors like colorectal and lung cancers.

Positive

• G1 Therapeutics is advancing its commercial-stage product COSELA™, demonstrating a commitment to oncology innovation.
• The company has a diverse clinical pipeline aimed at treating various solid tumors, which could lead to increased market opportunities.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2021 on Wednesday, February 23, 2022 at 8:30 a.m. ET.

The live call may be accessed by dialing (866) 763-6020 (domestic) or (409) 216-0626 (international) and entering the conference code: 5256086. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com

Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com  

FAQ

When is the G1 Therapeutics Q4 2021 earnings call scheduled?

The G1 Therapeutics Q4 2021 earnings call is scheduled for February 23, 2022, at 8:30 a.m. ET.

How can I access the G1 Therapeutics earnings call?

You can access the G1 Therapeutics earnings call by dialing (866) 763-6020 for domestic calls or (409) 216-0626 for international calls, using conference code 5256086.

What is COSELA™ and its significance for G1 Therapeutics?

COSELA™ (trilaciclib) is G1 Therapeutics' first commercial product aimed at improving the lives of cancer patients, with a focus on various solid tumors.